Alivion, an ETH Spin-off, develops handheld devices to detect biomarkers in breath to define individual fat-burns rate for personalized weight management. Target market: weight management monitoring for diets (incl. GLP-1), fitness & sports, longevity enhusiasts (market potential > $70bn; double digit growth). Business model (B2B; non-medical): Phase 1: Sales of handheld devices 'Nutrion' through distributor to dieticians & endocrinologists and App subscription for gameification and recommendations (and advertisment income from Freemium App); Phase 2: Sales of 'Neo' device and App Subscription for B2B2C (non-medical) for sports and longevity enhusisasts.
Alivion: The Venture Leader Mobile developing handheld devices for personalized weight management (venturelab.swiss)
Venturelab starts 2025 internationally with the Venture Leaders Mobile kick-off (venturelab.swiss)
Several CLAs signed for 3rd financing round covering >20% of financial round
Prof. Dr. Felix Beuschlein (Clinic Director USZ Endocrinology) & Dr. Willy Bischofberger (Lealy Founder) join Advisory Board
Partnership negotiations with international analytical instrumentation company in place
37 pre-launch-orders of Nutrion, Core App and Insights Browswer Software
Venture Lab Mobile 2025: Alivion wins 1st price '4YFN' from Madrid Business School (out of 50 applicants)
1st price: ISPO Award Winner: Brand New Award (Munich, Germany)
first CLA signed and soft committments for 3rd financing round Alivion
Advisory Board established (Prof. Dr. med. Peter Ryser; Dr. med. Susanne Maurer; Thomas Schulz; Prof. Dr. Andreas Güntner; Brad Root (USA))
Distribution agreeement signed with Gerber Instruments for sales of Spark M-20/M-30
Diet study started for fat-burn rate definition with USZ (Innosuisse Grant)
Alivion QMS released
10 breath analysis instruments produced for USZ study and verification done
100 Spark M-20/M-30 sold to more than 30 countries; no quality issues reported
Spark M-20/M-30 launched and technical validation done